Literature DB >> 31651280

The value of GRASP on DCE-MRI for assessing response to neoadjuvant chemotherapy in patients with esophageal cancer.

Yanan Lu1, Ling Ma2, Jianjun Qin3,4, Zhaoqi Wang1, Jia Guo1, Yan Zhao1, Hongkai Zhang1, Xu Yan5, Hui Liu1, Hailiang Li1, Ihab R Kamel6, Jinrong Qu7.   

Abstract

BACKGROUND: To compare the value of two dynamic contrast-enhanced Magnetic Resonance Images (DCE-MRI) reconstruction approaches, namely golden-angle radial sparse parallel (GRASP) and view-sharing with golden-angle radial profile (VS-GR) reconstruction, and evaluate their values in assessing response to neoadjuvant chemotherapy (nCT) in patients with esophageal cancer (EC).
METHODS: EC patients receiving nCT before surgery were enrolled prospectively. DCE-MRI scanning was performed after nCT and within 1 week before surgery. Tumor Regression Grade (TRG) was used for chemotherapy response evaluation, and patients were stratified into a responsive group (TRG1 + 2) and a non-responsive group (TRG3 + 4 + 5). Wilcoxon test was utilized for comparing GRASP and VS-GR reconstruction, Kruskal-Wallis and Mann-Whitney test was performed for each parameter to assess response, and Spearman test was performed for analyzing correlation between parameters and TRGs, as well as responder and non-responder. The receiver operating characteristic (ROC) was utilized for each significant parameter to assess its accuracy between responders and non-responders.
RESULTS: Among the 64 patients included in this cohort (52 male, 12 female; average age of 59.1 ± 7.9 years), 4 patients showed TRG1, 4 patients were TRG2, 7 patients were TRG3, 11 patients were TRG4, and 38 patients were TRG5. They were stratified into 8 responders and 56 non-responders. A total of 15 parameters were calculated from each tumor. With VS-GR, 10/15 parameters significantly correlated with TRG and response groups. Of these, only AUCmax showed moderate correlation with TRG, 7 showed low correlation and 2 showed negligible correlation with TRG. 8 showed low correlation and 2 showed negligible correlation with response groups. With GRASP, 13/15 parameters significantly correlated with TRG and response groups. Of these, 10 showed low correlation and 3 showed negligible correlation with TRG. 11 showed low correlation and 2 showed negligible correlation with TRG. Seven parameters (AUC* > 0.70, P < 0.05) showed good performance in response groups.
CONCLUSIONS: In patients with esophageal cancer on neoadjuvant chemotherapy, several parameters can differentiate responders from non-responders, using both GRASP and VS-GR techniques. GRASP may be able to better differentiate these two groups compared to VS-GR. Trial registration for this prospective study: ChiCTR, ChiCTR-DOD-14005308. Registered 2 October 2014.

Entities:  

Keywords:  Chemotherapy; Esophageal Cancer; Magnetic resonance imaging; Neoadjuvant therapy; Treatment outcome

Mesh:

Substances:

Year:  2019        PMID: 31651280      PMCID: PMC6814031          DOI: 10.1186/s12885-019-6247-3

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


Background

Esophageal cancer (EC) has become the eighth most common cancer, and the incidence rate is rising rapidly worldwide [1]. Squamous cell carcinoma (SCC) is the main pathological type of EC in China, and is a high-grade malignancy with rapid progression, poor response and high recurrence rate [2, 3]. Moreover, SCC is associated with limited quality of life after surgery, poor prognosis [4] and a high incidence of postoperative morbidity and mortality [5-7]. Ando et al. reported that nCT before resection is still the main treatment for stages II and III SCC [7, 8]. If local tumor is controlled, nCT followed by surgical procedures is an optimum treatment strategy, which can improve overall survival for patients with SCC [8]. Predicting response to nCT accurately helps clinicians to provide the best treatment approach such as modification of nCT, or termination of nCT to initiate surgical resection [1, 9]. 18 F-fluorodeoxyglucose positron emission tomography (18 F-FDG-PET) shows to be a promising technique for predicting therapeutic response, but standardizing protocols and the time of scanning is required [10]. Dynamic contrast-enhanced Magnetic Resonance Images (DCE-MRI) have the ability to predict an early response in EC following 3 weeks of concurrent chemoradiotherapy in limited cases [11, 12]. However, it is still challenging to non-invasively predict response to nCT. Recently, golden-angle radial sparse parallel (GRASP) MRI has gained interest, and has been applied to imaging of the liver, rectal cancer and renal cell carcinoma [13-16]. GRASP is capable of reconstructing the acquired data at very high temporal resolution using only a small number of radial spokes for every temporal frame. This enables high-resolution free-breathing perfusion imaging with higher in-plane spatial resolution and thinner partitions. This results in near-isotropic resolution, compared with the current view-sharing with golden-angle radial profile (VS-GR) reconstruction, without the current imaging constraints of breath-holding techniques [13]. The aim of this study was to compare DCE-MRI with GRASP reconstruction to DCE-MRI with VS-GR reconstruction in assessing response to nCT in patients with EC and to identify DCE-MRI parameters that can differentiate responders from non-responders.

Methods

This prospective study was approved by the Ethics Committee of Henan Cancer Hospital (No.20140303), and written informed consent was obtained from all participants. Those patients who received nCT followed by surgical resection were enrolled. DCE-MRI was performed within 1 week before surgery. All studies were performed between September 2015 and March 2017. The inclusion criteria were following [17]: 1) Patients were confirmed with stage II-III EC by esophagoscopy pathologically [18, 19], 2) 2 cycles of nCT before surgery were performed, 3) Imaging and clinical response evaluation were performed at 2 weeks after completing all the treatment. (Fig. 1).
Fig. 1

Flow chart illustrates patient selection process for study cohort

Flow chart illustrates patient selection process for study cohort

DCE-MRI scanning methods

DCE-MRI examination was performed on a 3 T MR scanner (MAGNETOM Skyra, Siemens Healthcare) with dynamic contrast-enhanced Radial VIBE free breathing, and an 18-element body matrix coil and an inbuilt 32-element spine matrix coil were used. Radial VIBE sequence parameters were following: TR: 3.98 ms TE: 1.91 ms, flip angle: 12°, acquisition matrix: 300 × 300, FOV: 300 mm × 300 mm × 146 mm, slice thickness: 3 mm, reconstructed image voxel size: 1.0 × 1.0 × 3.0 mm3, radial views: 1659, scanning time: 309 s. A total of 68 period images were collected, and each period included 72 images. 10-15 mL Gadopentetate Dimeglumine Injection (0.2 ml/kg of body weight, Omniscan, GE Healthcare) was injected at a rate of 2.5 mL/s, followed by equal volume of normal saline solution to flush the tube at 20 s after the beginning of scanning by a MR-compatible automated high-pressure injector (Spectris Solaris EP, Medrad) [17].

Histopathology response

Pathologic response was assessed as 5 grades according to Tumor Regression Grade (TRG) [20]: TRG 1 (complete regression) showed absence of residual cancer and fibrosis extending through the different layers of the esophageal wall; TRG 2 was characterized by the presence of rare residual cancer cells scattered through bands of fibrosis; TRG 3 was characterized by an increase in the number of residual cancer cells, but fibrosis still predominated; TRG 4 showed residual cancer outgrowing fibrosis; and TRG 5 was characterized by absence of regressive changes. They were stratified into a responsive group (TRG1 + 2) and a non-responsive group (TRG3 + 4 + 5).

Image processing and data analysis

The radial views (1659 of stack-of-stars views acquired from DCE-MRI) were input into online reconstruction pipeline of view sharing reconstruction and regrouped into 2 sub-frames (sub-frame-1: T0-T61 with a temporal resolution of 2.4 s, sub-frame 2 from T62-T68 with temporal resolution of 21.7 s). A home setup of GRASP reconstruction processing pipeline (https://mrirecon.github.io/bart/) post processed on a Yarra server (https://yarra.rocks) were used for GRASPs offline, with the same data but using a temporal resolution of 4.5 s (Table 1).
Table 1

Details of reconstruction setting for radial VIBE with golden angle stack-of-stars sampling scheme

View-SharingGRASP
number of acquired views1659
FOV300 mm × 300 mm × 146 mm
spatial resolution1.0 × 1.0 × 3.0 mm3
temporal resolution2.4 s/21.7 s4.5 s
number of dynamic volumes6868
Reconstruction modeOnlineOffline
Reconstruction timeN/A62 minutes on a CPU server

Note: The temporal resolution of VS-GR means the starting time interval between two phases, however, 90% of the prior phase was overlapped with this phase. So, although the temporal resolution of VS-GR seems very short, actually it is longer

Details of reconstruction setting for radial VIBE with golden angle stack-of-stars sampling scheme Note: The temporal resolution of VS-GR means the starting time interval between two phases, however, 90% of the prior phase was overlapped with this phase. So, although the temporal resolution of VS-GR seems very short, actually it is longer The images reconstructed by two different approaches, namely GRASP and VS-GR, were processed by Omni-Kinetics software (GE Medical, China) to segment the tumor and generate pharmacokinetic parameters respectively. The thoracic aorta was selected to obtain the arterial input function (AIF), since the esophageal artery is not easy to identify. Figure 2 shows the AIFs derived from GRASP and VS-GR reconstructions from the same contrast-enhanced study.
Fig. 2

Arterial contrast concentration curve from GRASP (red) and view-sharing (blue) reconstruction using the same dynamic acquisition. GRASP’s AIF is closer to the true AIF with steeper slope and sharp peak than view-sharing

Arterial contrast concentration curve from GRASP (red) and view-sharing (blue) reconstruction using the same dynamic acquisition. GRASP’s AIF is closer to the true AIF with steeper slope and sharp peak than view-sharing Two radiologists with more than 10 years experiences in thorax radiology segmented the 3D- regions of interest (ROI) manually. The radiologists were blinded to clinical data, and were asked to include the entire tumor on each slice post-nCT, except areas of necrotic degeneration or cystic and normal blood vessels. The pharmacokinetic parameters were generated by using Tofts model.

Statistical analysis

SPSS Statistics version 22 (IBM Corp., Armonk, NY, USA) were used to perform statistical analysis in this study. Interobserver reproducibility of pharmacokinetic parameters was assessed by inter-class correlation coefficients (ICCs). An ICC > 0.75 was considered good agreement. The Wilcoxon test of was used to compare the various parameters between VS-GR and GRASP reconstruction, and Kruskal-Wallis test for DCE-MRI parameters with VS-GR or GRASP reconstruction among the TRG1–5 groups (P < 0.05). Mann-Whitney test was for analyzing the differences between responder and non-responder groups. Spearman test was performed for correlation analysis between DCE-MRI parameters and TRGs, or response groups. Spearman’s correlation coefficients were assessed as follows: a correlation coefficient of 0.90–1.00 is considered very high; 0.70–0.89, high; 0.50–0.69, moderate; 0.30–0.49, low; and 0–0.29, negligible [21]. The receiver operating characteristic (ROC) was adopted to assess the value of each parameter in predicting response (AUC*>0.50, P<0.05).

Results

Among the total of 64 patients (52 male, 12 female, average age of 59.1 ± 7.9 years), 59 patients had SCC, 2 patients had adenocarcinoma and 3 patients had adenosquamous carcinoma. According to pathologic response, 4 patients showed TRG1, 4 patients were TRG2, 7 patients were TRG3, 11 patients were TRG4, and 38 patients were TRG5. They were stratified into 8 responders and 56 non-responders (Table 2).
Table 2

Patients’ demographic information and TRG

Study population
Gender
 Male52
 Female12
 Age, years59.1 ± 7.9
Clinical T-stage
 T12
 T215
 T342
 T45
Clinical N-stage
 No32
 N115
 N215
 N32
Type
 SCC59
 AC2
 ASC3
Tumor Regression Grade
 14
 24
 37
 411
 538
Patients’ demographic information and TRG ICCs showed the excellence of 15 pharmacokinetic parameters from the two reconstructions as assessed by the two radiologists, and the kappa value was 0.918.

Comparison of DCE-MRI parameters with VS-GR and GRASP reconstruction groups

GRASP showed a better AIF curve with steeper slope and sharper peak compared to VS-GR (Fig. 2). A total of 15 pharmacokinetic parameters were extracted from each tumor. 14 of these showed statistically significant difference for both VS-GR and GRASP reconstruction across the TRG groups. Only plasma volume fraction (Vp) max did not show a significant difference (P = 0.628).

Comparison among TRG1–5 for DCE-MRI parameters with VS-GR and GRASP reconstruction

14/15 DCE-MRI parameters both with VS-GR and with GRASP reconstruction showed significant inter-groups difference by TRG 1–5 (P < 0.05), except for Ve max which showed not significant inter-groups difference by TRG 1–5 (Table 3).
Table 3

Differences among TRG1–5 for DCE-MRI parameters with VS-GR and GRASP reconstruction

parametersVS-GR reconstructionGRASP reconstruction
TRG1TRG2TRG3TRG4TRG5χ2P valueTRG1TRG2TRG3TRG4TRG5χ2P value
Ktrans max0.000 (0.000,0.099)1.075 (0.630,1.643)0.713 (0.553,1.405)2.477 (1.800,5.000)2.396 (1.357,3.420)20.101<0.0010.000 (0.000,0.086)0.159 (0.100,0.304)0.170 (0.117,0.207)0.324 (0.198,0.905)0.310 (0.200,0.424)15.5330.004
Ktrans mean0.000 (0.000,0.037)0.277 (0.105,0.343)0.189 (0.094,0.369)0.239 (0.200,0.549)0.315 (0.166,0.405)12.3680.0150.000 (0.000,0.027)0.055 (0.030,0.106)0.044 (0.025,0.068)0.060 (0.045,0.126)0.074 (0.051,0.095)13.4320.009
Ktrans 75%0.000 (0.000,0.052)0.359 (0.123,0.467)0.307 (0.123,0.491)0.372 (0.271,0.572)0.422 (0.200,0.562)12.3130.0150.000 (0.000,0.034)0.082 (0.043,0.129)0.056 (0.033,0.082)0.074 (0.060,0.160)0.091 (0.065,0.122)12.5310.014
Kep max0.000 (0.000,0.200)3.131 (2.127,5.898)2.208 (1.657,3.024)4.506 (2.729,7.424)4.868 (2.823,6.578)16.6840.0020.000 (0.000,0.489)0.810 (0.543,1.410)0.929 (0.580,1.121)1.543 (1.010,1.985)1.390 (0.854,1.877)14.4550.006
Kep mean0.000 (0.000,0.002)0.723 (0.388,0.824)0.215 (0.113,0.493)0.349 (0.252,1.185)0.537 (0.361,0.844)15.0880.0050.000 (0.000,0.123)0.294 (0.167,0.558)0.212 (0.167,0.455)0.272 (0.213,0.434)0.331 (0.227,0.432)10.3580.035
Kep 75%0.000 (0.000,0.005)1082 (0.833,1.568)0.361 (0.010,0.799)0.539 (0.327,1.571)0.897 (0.545,1.361)15.2540.0040.000 (0.000,0.160)0.472 (0.262,0.664)0.277 (0.228,0.532)0.358 (0.274,0.552)0.451 (0.282,0.540)11.0330.026
Ve max1.000 (0.510,1.000)1.000 (1.000,1.000)1.000 (1.000,1.000)1.000 (1.000,1.000)1.000 (1.000,1.000)7.1800.1271.000 (1.000,1.000)0.824 (0.376,1.000)1.000 (0.417,1.000)1.000 (1.000,1.000)1.000 (0.826,1.000)3.4470.486
Ve mean0.000 (0.000,0.002)O.349 (0.111,0.438)0.369 (0.139,0.434)0.331 (0.256,0.386)0.317 (0.203,0.359)11.5520.0210.000 (0.000,0.200)0.196 (0.150,0.207)0.189 (0.159,0.275)0.230 (0.199,0.303)0.230 (0.199,0.287)9.8090.044
Ve 75%0.000 (0.000,0.0007)0.387 (0.064,0.555)0.505 (0.001,0.604)0.503 (0.373,0.570)0.468 (0.303,0.508)11.4780.0220.000 (0.000,0.214)0.220 (0.175,0.250)0.219 (0.180,0.305)0.257 (0.163,0.311)0.256 (0.219,0.328)8.5180.074
Vp max0.000 (0.000,0.007)0.067 (0.033,0.115)0.058 (0.041,0.101)0.244 (0.056,0.630)0.143 (0.073,0.249)14.1980.0070.000 (0.000,0.034)0.066 (0.050,0.104)0.082 (0.045,0.137)0.205 (0.103,0.335)0.134 (0.090,0.236)16.5810.002
Vp mean0.000 (0.000,0.0001)0.004 (0.001,0.007)0.001 (0.001,0.007)0.003 (0.000,0.009)0.002 (0.000,0.005)9.7720.0440.000 (0.000,0.001)0.009 (0.003,0.015)0.003 (0.001,0.027)0.019 (0.006,0.063)0.014 (0.009,0.016)17.0410.002
Vp 75%0.000 (0.000,0.0007)0.001 (0.001,0.004)0.001 (0.001,0.006)0.001 (0.001,0.001)0.001 (0.001,0.001)9.6020.0480.000 (0.000,0008)0.011 (0.003,0.022)0.001 (0.001,0.041)0.033 (0.007,0.080)0.023 (0.014,0.038)17.5230.002
AUC max0.000 (0.000,0.316)0.071 (0.059,0.089)0.083 (0.070,0.089)0.101 (0.090,0.119)0.121 (0.089,0.147)21.365<0.0010.000 (0.000,1.619)1.738 (0.974,2.350)3.344 (2.259,6.248)4.561 (2.326,6.424)3.364 (2.516,4.512)16.4540.002
AUC mean0.000 (0.000,0.012)0.036 (0.018,0.045)0.043 (0.026,0.045)0.369 (0.032,0.041)0.040 (0.029,0.047)11.4450.0220.000 (0.000,0.793)0.940 (0.562,1.469)1.473 (1.036,1.617)1.688 (1.035,2.375)1.538 (1.190,1.875)12.6050.013
AUC 75%0.000 (0.000,0.015)0.045, (0.025,0.056)0.052 (0.034,0.054)0.047 (0.041,0.056)0.053 (0.038,0.061)11.9800.0180.000 (0.000,0.965)1.180 (0.734,1.661)1.642 (1.232,1.981)2.041 (1.234,2.748)1.854 (1.417,2.149)12.9940.011

Note. —Data are median (P25, P75)

Differences among TRG1–5 for DCE-MRI parameters with VS-GR and GRASP reconstruction Note. —Data are median (P25, P75)

Comparison between responder and non-responder groups for DCE-MRI parameters with VS-GR/ GRASP reconstruction

Ten parameters with VS-GR reconstruction showed significant differences between responders and non-responders, which including volume transfer constant (Ktrans) max, Ktrans mean, Ktrans 75%, intravasation rate contrast (Kep) max, extravascular extracellular volume fraction (Ve) mean, Ve 75%, Vp max, the initial area-under-the- concentration versus time curve (AUC) max, AUC mean, AUC 75%. 13 parameters with GRASP reconstruction showed significant differences between responders and non-responders, which including Ktrans max, Ktrans mean, Ktrans 75%, Kep max, Kep mean, Ve mean, Ve 75%, Vp max, Vp mean, Vp 75%, AUC max, AUC mean, AUC 75% (Table 4).
Table 4

Differences between responder and non-responder groups for DCE-MRI parameters with VS-GR/GRASP reconstruction

parametersVS-GR reconstructionGRASP reconstruction
respondernon-responderU valueP valuerespondernon-responderU valueP value
Ktrans max0.314 (0.000,1.097)2.303 (1.172,3.564)51.0<0.0010.101 (0.000,0.189)0.304 (0.196,0.415)69.00.002
Ktrans mean0.055 (0.000,0.298)0.299 (0.157,0.387)92.00.0070.031 (0.000,0.067)0.065 (0.046,0.094)104.00.015
Ktrans 75%0.069 (0.000,0.395)0.404 (0.200,0.545)92.00.0070.043 (0.000,0.097)0.082 (0.061,0.121)115.00.027
Kep max1.088 (0.000,3.309)4.272 (2.307,6.527)90.00.0070.559 (0.000,0.934)1.342 (0.861,1.875)75.00.002
Kep mean0.149 (0.000,0.751)0.506 (0.251,0.823)140.00.0880.160 (0.000,0.340)0.318 (0.212,0.432)117.00.030
Kep 75%0.384 (0.000,1.095)0.772 (0.363,1.334)154.00.1550.215 (0.000,0.509)0.429 (0.268,0.536)137.00.077
Ve max1.000 (1.000,1.000)1.000 (1.000,1.000)199.50.0991.000 (0.736,1.000)1.000 (0.875,1.000)223.00.979
Ve mean0.030 (0.000,0.388)0.323 (0.201,0.370)124.00.0420.163 (0.000,0.207)0.227 (0.189,0.276)93.00.008
Ve 75%0.006 (0.000,0.471)0.475 (0.297,0.521)112.00.0230.187 (0.000,0.250)0.250 (0.209,0.311)104.00.015
Vp max0.017 (0.000,0.068)0.140 (0.056,0.316)71.00.0020.046 (0.000,0.070)0.133 (0.085, 0.233)63.00.001
Vp mean0.0004 (0.0000,0.0048)0.002 (0.001,0.006)135.00.0710.001 (0.000,0.009)0.014 (0.008,0.030)67.00.001
Vp 75%0.001 (0.001,0.001)0.001 (0.001,0.001)142.00.0960.001 (0.000,0.012)0.023 (0.008,0.042)65.00.001
AUC max0.050 (0.000,0.076)0.108 (0.085,0.137)40.0<0.0011.062 (0.000,2.220)3.424 (2.489,4.832)31.0<0.001
AUC mean0.016 (0.000,0.040)0.039 (0.030,0.047)90.00.0070.569 (0.000,1.236)1.515 (1.188,1.901)60.00.001
AUC 75%0.020 (0.000,0.049)0.052 (0.052,0.060)86.00.0050.753 (0.000,1.497)1.854 (1.403,2.203)55.00.001

Note. —Data are median (P25, P75)

Differences between responder and non-responder groups for DCE-MRI parameters with VS-GR/GRASP reconstruction Note. —Data are median (P25, P75)

Correlation between parameters with VS-GR/GRASP reconstruction and TRG/response

With VS-GR, 10/15 parameters significantly correlated with TRG and response groups. Of these, only AUCmax showed moderate correlation with TRG, 7 showed low correlation and 2 showed negligible correlation with TRG. 8 showed low correlation and 2 showed negligible correlation with response groups. With GRASP, 13/15 parameters significantly correlated with TRG and response groups. Of these, 10 showed low correlation and 3 showed negligible correlation with TRG. 11 showed low correlation and 2 showed negligible correlation with TRGs (Table 5).
Table 5

DCE-MRI parameters with VS-GR/GRASP stratified according to TRGs and response

ParametersTRG1–5responder and non-responder
VS-GRGRASPVS-GRGRASP
r*(P)r* (P)r* (P)r* (P)
Ktrans max0.409 (0.001)0.343 (0.006)0.443(< 0.001)0.396 (0.001)
Ktrans mean0.305 (0.014)0.320 (0.010)0.338 (0.006)0.307 (0.014)
Ktrans 75%0.318 (0.011)0.282 (0.024)0.338 (0.006)0.279 (0.026)
Kep max0.379 (0.002)0.323 (0.009)0.343 (0.006)0.381 (0.002)
Kep mean0.314 (0.012)0.255 (0.042)0.215 (0.088)0.274 (0.029)
Kep 75%0.283 (0.023)0.238 (0.058)0.179 (0.157)0.223 (0.077)
Ve max0.097 (0.446)−0.035 (0.784)0.208 (0.099)−0.003 (0.979)
Ve mean0.125 (0.324)0.318 (0.010)0.256 (0.041)0.335 (0.007)
Ve 75%0.151 (0.234)0.330 (0.008)0.286 (0.022)0.307 (0.014)
Vp max0.312 (0.012)0.333 (0.007)0.391 (0.001)0.412 (0.001)
Vp mean0.158 (0.213)0.371 (0.003)0.228 (0.070)0.402 (0.001)
Vp 75%0.115 (0.366)0.370 (0.003)0.210 (0.096)0.407 (0.001)
AUC max0.524(< 0.001)0.253 (0.044)0.471(< 0.001)0.494(< 0.001)
AUC mean0.294 (0.018)0.306 (0.014)0.343 (0.006)0.419 (0.001)
AUC 75%0.314 (0.012)0.307 (0.014)0.353 (0.004)0.432(< 0.001)

Note.—r* is the Spearman correlation coefficient obtained from the nonparametric Spearman correlation test

DCE-MRI parameters with VS-GR/GRASP stratified according to TRGs and response Note.—r* is the Spearman correlation coefficient obtained from the nonparametric Spearman correlation test

Diagnostic performance of DCE-MRI parameters with VS-GR/ GRASP reconstruction between responder and non-responder groups

Seven parameters with VS-GR/GRASP reconstruction showed good or excellent diagnostic performance between responders and non-responders, which including Ktrans max, Ktrans mean, Kep max, Vp max, AUC max, AUC mean, AUC 75%. In general, the seven variables had similar diagnostic performance in the two reconstructions. Among the seven variables, AUC max showed excellent performance in response groups (AUC*>0.90, P<0.05) (Table 6).
Table 6

Diagnostic performance of DCE-MRI parameters with VS-GR/GRASP according to response groups

ParametersSensitivity (%)Speciticity (%)AUC* P
VS-GRGRASPVS-GRGRASPVS-GRGRASP
Ktrans max87.575.076.885.70.8860.8460.464
Ktrans mean62.575.098.283.90.7950.7680.634
Ktrans 75%62.575.098.278.60.7950.7430.256
Kep max50.075.0100.083.90.7990.8330.708
Kep mean50.075.0100.076.80.6870.7390.566
Kep 75%50.062.5100.087.50.6560.6940.658
Ve max12.587.5100.03.60.5550.5020.604
Ve mean62.587.598.264.30.7230.7920.672
Ve 75%75.075.078.667.90.7500.7680.905
Vp max87.587.571.478.60.8420.8590.785
Vp mean62.562.585.796.40.6990.8500.221
Vp 75%62.562.582.198.20.6830.8550.211
AUC max87.5100.082.180.40.9110.9310.580
AUC mean62.562.596.498.20.7990.8660.249
AUC 75%62.562.596.498.20.8080.8770.280
Diagnostic performance of DCE-MRI parameters with VS-GR/GRASP according to response groups

Discussion

This study demonstrated that GRASP reconstruction may affect the results of DCE-MRI, DCE-MRI with VS-GR and GRASP reconstruction could assess tumor response, and pharmacokinetic parameters with GRASP and VS-GR reconstruction may help stratify responders from non-responders in patients with EC treated by nCT. In this study, 10 post-nCT pharmacokinetic parameters with VS-GR reconstruction and 13 parameters with GRASP reconstruction showed statistically significant differences between responders and non-responders. Moreover, GRASP reconstruction provided more parameters than VS-GR reconstruction. However, seven parameters with VS-GR/GRASP reconstruction showed good or excellent diagnostic performance between responders and non-responders and no significant difference in diagnostic performance between VS-GR and GRASP reconstructions. Most DCE-MRI studies only analyzed parts of parameters, such as Ktrans mean, kep mean, Ve mean, and AUC, and showed DCE-MRI could assess the response to therapy [22]. In the current study, we tried to analyze more parameters acquired from DCE-MRI, and 15 parameters were analyzed. It was reported that DCE-MRI with GRASP reconstruction could provide near-isotropic resolution and higher in-plane spatial resolution [13]. Contribution to the VS-GR images with a 2.1 s apparent temporal resolution is from a ~ 21 s time footprint acquisition, while GRASP is reconstructed from a 4.5 s time footprint, higher temporal resolution normally leads to an improved AIF, which is used for more accurate pharmacokinetics parameters calculation [23]. Compared to conventional VS-GR DCE-MRI, this could result in better acquisition of pharmacokinetic parameters potentially which has been reported in hepatocellular carcinoma, renal cell carcinoma and rectal cancer [13] [16] [15]. VS-GR DCE-MRI had been used in EC [12], however, GRASP reconstruction has not been reported to be compared with VS-GR reconstruction in EC. The AIF plays an important role for the pharmacokinetic models in determining the quantitative measurements of physiological parameters, where small differences in AIF may lead to large differences in quantitative maps and higher temporal resolution gives smaller differences. More parameters with GRASP showed significant correlation with TRGs and response groups than those with VS-GR reconstruction. Both 10/15 parameters with VS-GR reconstruction showed significant correlation with TRGs and response groups, and both 13/15 parameters with GRASP reconstruction showed significant correlation with TRGs and response groups. It may be the effect of GRASP reconstruction, providing higher time resolution and more information. It is critical to detecting residual cancer post-nT. Fortunately, some pharmacokinetic parameters between TGRs showed significant differences in this study. The information of whole tumor, rather than a single axial level, was assessed in our study, which theoretically provides a more comprehensive representation of tumor information than that provided by a single-level analysis. FDG-PET have been used for neoadjuvant treatment response assessment in EC [24], and the FDG-PET response after neoadjuvant treatment could predict the pathological response and seems to be related to survival [25-27]. However, Van Rossum et al. showed that accuracy of imaging is insufficient in predicting pathologic response [28], and the prognostic value of FDG-PET response after chemoradiotherapy has not been definitively established [29, 30]. There were several limitations in this study. First, one critical step in quantifying DCE MRI parameters is to sample AIF from a major artery. However, to sample AIF in esophageal images can be challenging, because of its small size. Li et al. showed automatically sampling AIF by utilizing temporal and spatial features in a multistep interleaved manner, that highly resembled those manually sampled ones in lower extremity arteries [31]. Second, limited sample size, the number of TRG1 in particular, may lead to bias. Finally, GRASP reconstruction required offline reconstruction, more computing ability and more time for reconstruction.

Conclusions

Several pharmacokinetic parameters of DCE-MRI reconstructed by GRASP and VS-GR show significant differences between TRGs and response groups and thus can be used to non-invasively predict tumor response. GRASP reconstruction provided more parameters than VS-GR reconstruction, which maybe showed additionally significant merit, and larger sample size study need to assess it furtherly.
  30 in total

Review 1.  Positron emission tomography imaging for gastroesophageal junction tumors.

Authors:  Abraham J Wu; Karyn A Goodman
Journal:  Semin Radiat Oncol       Date:  2013-01       Impact factor: 5.934

2.  Statistics corner: A guide to appropriate use of correlation coefficient in medical research.

Authors:  M M Mukaka
Journal:  Malawi Med J       Date:  2012-09       Impact factor: 0.875

3.  Impact of esophagectomy for cancer on patients' occupational status.

Authors:  E Pinto; F Cavallin; R Alfieri; L M Saadeh; S Mantoan; M Cagol; C Castoro; M Scarpa
Journal:  Eur J Surg Oncol       Date:  2015-10-09       Impact factor: 4.424

4.  Quantitative Perfusion Analysis of the Rectum Using Golden-Angle Radial Sparse Parallel Magnetic Resonance Imaging: Initial Experience and Comparison to Time-Resolved Angiography With Interleaved Stochastic Trajectories.

Authors:  Ulrike I Attenberger; Jing Liu; Philipp Riffel; Johannes Budjan; Robert Grimm; Kai T Block; Stefan O Schoenberg; Xiaoying Wang; Daniel Hausmann
Journal:  Invest Radiol       Date:  2017-12       Impact factor: 6.016

5.  Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?

Authors:  Helen M Heneghan; Claire Donohoe; Jessie Elliot; Zuhair Ahmed; Vinod Malik; Narayamasamy Ravi; John V Reynolds
Journal:  Ann Surg       Date:  2016-11       Impact factor: 12.969

6.  Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma.

Authors:  Jane M Blazeby; Emma Sanford; Stephen J Falk; Derek Alderson; Jenny L Donovan
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

7.  Assessment of esophageal carcinoma undergoing concurrent chemoradiotherapy with quantitative dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Jing Lei; Qian Han; Shaocheng Zhu; Dapeng Shi; Shewei Dou; Zihua Su; Xiao Xu
Journal:  Oncol Lett       Date:  2015-10-05       Impact factor: 2.967

8.  Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer.

Authors:  Thomas W Rice; Hemant Ishwaran; Mark K Ferguson; Eugene H Blackstone; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2016-10-31       Impact factor: 15.609

9.  Salvage Esophagectomy After Definitive Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Who Really Benefits from this High-Risk Surgery?

Authors:  Masayuki Watanabe; Shinji Mine; Koujiro Nishida; Kazuhiko Yamada; Hironobu Shigaki; Akira Matsumoto; Takeshi Sano
Journal:  Ann Surg Oncol       Date:  2015-04-11       Impact factor: 5.344

10.  "One-Stop Shop": Free-Breathing Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Kidney Using Iterative Reconstruction and Continuous Golden-Angle Radial Sampling.

Authors:  Philipp Riffel; Frank G Zoellner; Johannes Budjan; Robert Grimm; Tobias K Block; Stefan O Schoenberg; Daniel Hausmann
Journal:  Invest Radiol       Date:  2016-11       Impact factor: 6.016

View more
  5 in total

1.  The value of intravoxel incoherent motion diffusion-weighted imaging in predicting the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.

Authors:  Tao Song; Qi Yao; Jinrong Qu; Hongkai Zhang; Yan Zhao; Jianjun Qin; Wen Feng; Shouning Zhang; Xianhua Han; Shaoyu Wang; Xu Yan; Hailiang Li
Journal:  Eur Radiol       Date:  2020-09-08       Impact factor: 5.315

2.  Diagnostic Performance of Vascular Permeability and Texture Parameters for Evaluating the Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma.

Authors:  Wenbing Ji; Jian Wang; Rongzhen Zhou; Minke Wang; Weizhen Wang; Peipei Pang; Min Kong; Chao Zhou
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

3.  Regional Differences in Blood-Brain Barrier Permeability in Cognitively Normal Elderly Subjects: A Dynamic Contrast-Enhanced MRI-Based Study.

Authors:  Il Heon Ha; Changmok Lim; Yeahoon Kim; Yeonsil Moon; Seol Heui Han; Won Jin Moon
Journal:  Korean J Radiol       Date:  2021-03-09       Impact factor: 3.500

4.  DCE-MRI of esophageal carcinoma using star-VIBE compared with conventional 3D-VIBE.

Authors:  He-Ping Deng; Xue-Ming Li; Liu Yang; Yi Wang; Shao-Yu Wang; Peng Zhou; Yu-Jie Lu; Jin Ren; Min Wang
Journal:  Sci Rep       Date:  2021-12-16       Impact factor: 4.379

Review 5.  [Alzheimer Dementia and Microvascular Pathology: Blood-Brain Barrier Permeability Imaging].

Authors:  Won-Jin Moon
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2020-05-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.